Mahesh Appari1, Astrid Breitbart1, Florian Brandes1, Malgorzata Szaroszyk1, Natali Froese1, Mortimer Korf-Klingebiel1, Mona Malek Mohammadi1, Andrea Grund1, Gesine M Scharf1, Honghui Wang1, Carolin Zwadlo1, Daniela Fraccarollo1, Ulrike Schrameck1, Mona Nemer1, G William Wong1, Hugo A Katus1, Kai C Wollert1, Oliver J Müller1, Johann Bauersachs1, Joerg Heineke2. 1. From the Klinik für Kardiologie und Angiologie (M.A., A.B., F.B., M.S., N.F., M.K.-K., M.M.M., A.G., G.M.S., H.W., C.Z., D.F., U.S., K.C.W., J.B., J.H.) and Cluster of Excellence REBIRTH (M.A., A.B., F.B., M.S., N.F., M.K.-K., M.M.M., A.G., G.M.S., H.W., C.Z., U.S., K.C.W., J.B., J.H.), Medizinische Hochschule Hannover, Germany; Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Heilongjiang, China (H.W.); Faculty of Medicine, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Canada (M.N.); Department of Physiology and Center for Metabolism and Obesity Research, The Johns Hopkins University School of Medicine, Baltimore, MD (G.W.W.); Department of Cardiology, University Hospital Heidelberg, Germany (H.A.K., O.J.M.); and DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Germany (H.A.K., O.J.M.). 2. From the Klinik für Kardiologie und Angiologie (M.A., A.B., F.B., M.S., N.F., M.K.-K., M.M.M., A.G., G.M.S., H.W., C.Z., D.F., U.S., K.C.W., J.B., J.H.) and Cluster of Excellence REBIRTH (M.A., A.B., F.B., M.S., N.F., M.K.-K., M.M.M., A.G., G.M.S., H.W., C.Z., U.S., K.C.W., J.B., J.H.), Medizinische Hochschule Hannover, Germany; Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Heilongjiang, China (H.W.); Faculty of Medicine, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Canada (M.N.); Department of Physiology and Center for Metabolism and Obesity Research, The Johns Hopkins University School of Medicine, Baltimore, MD (G.W.W.); Department of Cardiology, University Hospital Heidelberg, Germany (H.A.K., O.J.M.); and DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Germany (H.A.K., O.J.M.). Heineke.Joerg@Mh-Hannover.de.
Abstract
RATIONALE: Myocardial endothelial cells promote cardiomyocyte hypertrophy, possibly through the release of growth factors. The identity of these factors, however, remains largely unknown, and we hypothesized here that the secreted CTRP9 (C1q-tumor necrosis factor-related protein-9) might act as endothelial-derived protein to modulate heart remodeling in response to pressure overload. OBJECTIVE: To examine the source of cardiac CTRP9 and its function during pressure overload. METHODS AND RESULTS: CTRP9 was mainly derived from myocardial capillary endothelial cells. CTRP9 mRNA expression was enhanced in hypertrophic human hearts and in mouse hearts after transverse aortic constriction (TAC). CTRP9 protein was more abundant in the serum of patients with severe aortic stenosis and in murine hearts after TAC. Interestingly, heterozygous and especially homozygous knock-out C1qtnf9 (CTRP9) gene-deleted mice were protected from the development of cardiac hypertrophy, left ventricular dilatation, and dysfunction during TAC. CTRP9 overexpression, in turn, promoted hypertrophic cardiac remodeling and dysfunction after TAC in mice and induced hypertrophy in isolated adult cardiomyocytes. Mechanistically, CTRP9 knock-out mice showed strongly reduced levels of activated prohypertrophic ERK5 (extracellular signal-regulated kinase 5) during TAC compared with wild-type mice, while CTRP9 overexpression entailed increased ERK5 activation in response to pressure overload. Inhibition of ERK5 by a dominant negative MEK5 mutant or by the ERK5/MEK5 inhibitor BIX02189 blunted CTRP9 triggered hypertrophy in isolated adult cardiomyocytes in vitro and attenuated mouse cardiomyocyte hypertrophy and cardiac dysfunction in vivo, respectively. Downstream of ERK5, we identified the prohypertrophic transcription factor GATA4, which was directly activated through ERK5-dependent phosphorylation. CONCLUSIONS: The upregulation of CTRP9 during hypertrophic heart disease facilitates maladaptive cardiac remodeling and left ventricular dysfunction and might constitute a therapeutic target in the future.
RATIONALE: Myocardial endothelial cells promote cardiomyocyte hypertrophy, possibly through the release of growth factors. The identity of these factors, however, remains largely unknown, and we hypothesized here that the secreted CTRP9 (C1q-tumor necrosis factor-related protein-9) might act as endothelial-derived protein to modulate heart remodeling in response to pressure overload. OBJECTIVE: To examine the source of cardiac CTRP9 and its function during pressure overload. METHODS AND RESULTS:CTRP9 was mainly derived from myocardial capillary endothelial cells. CTRP9 mRNA expression was enhanced in hypertrophichuman hearts and in mouse hearts after transverse aortic constriction (TAC). CTRP9 protein was more abundant in the serum of patients with severe aortic stenosis and in murine hearts after TAC. Interestingly, heterozygous and especially homozygous knock-out C1qtnf9 (CTRP9) gene-deleted mice were protected from the development of cardiac hypertrophy, left ventricular dilatation, and dysfunction during TAC. CTRP9 overexpression, in turn, promoted hypertrophic cardiac remodeling and dysfunction after TAC in mice and induced hypertrophy in isolated adult cardiomyocytes. Mechanistically, CTRP9 knock-out mice showed strongly reduced levels of activated prohypertrophic ERK5 (extracellular signal-regulated kinase 5) during TAC compared with wild-type mice, while CTRP9 overexpression entailed increased ERK5 activation in response to pressure overload. Inhibition of ERK5 by a dominant negative MEK5 mutant or by the ERK5/MEK5 inhibitor BIX02189 blunted CTRP9 triggered hypertrophy in isolated adult cardiomyocytes in vitro and attenuated mouse cardiomyocyte hypertrophy and cardiac dysfunction in vivo, respectively. Downstream of ERK5, we identified the prohypertrophic transcription factor GATA4, which was directly activated through ERK5-dependent phosphorylation. CONCLUSIONS: The upregulation of CTRP9 during hypertrophic heart disease facilitates maladaptive cardiac remodeling and left ventricular dysfunction and might constitute a therapeutic target in the future.
Authors: Gesine M Scharf; Katja Kilian; Julio Cordero; Yong Wang; Andrea Grund; Melanie Hofmann; Natali Froese; Xue Wang; Andreas Kispert; Ralf Kist; Simon J Conway; Robert Geffers; Kai C Wollert; Gergana Dobreva; Johann Bauersachs; Joerg Heineke Journal: JCI Insight Date: 2019-07-16
Authors: Hannah C Little; Susana Rodriguez; Xia Lei; Stefanie Y Tan; Ashley N Stewart; Ageline Sahagun; Dylan C Sarver; G William Wong Journal: FASEB J Date: 2019-04-19 Impact factor: 5.191
Authors: Wenjun Yan; Yongzhen Guo; Ling Tao; Wayne Bond Lau; Lu Gan; Zheyi Yan; Rui Guo; Erhe Gao; G William Wong; Walter L Koch; Yajing Wang; Xin-Liang Ma Journal: Circulation Date: 2017-10-04 Impact factor: 29.690
Authors: Susana Rodriguez; Hannah C Little; Parnaz Daneshpajouhnejad; Blythe D Shepard; Stefanie Y Tan; Andrew Wolfe; Muhammad Umar Cheema; Sandeep Jandu; Owen M Woodward; C Conover Talbot; Dan E Berkowitz; Avi Z Rosenberg; Jennifer L Pluznick; G William Wong Journal: FASEB J Date: 2019-12-26 Impact factor: 5.191
Authors: Wei Liu; Andrea Ruiz-Velasco; Shoubao Wang; Saba Khan; Min Zi; Andreas Jungmann; Maria Dolores Camacho-Muñoz; Jing Guo; Guanhua Du; Liping Xie; Delvac Oceandy; Anna Nicolaou; Gina Galli; Oliver J Müller; Elizabeth J Cartwright; Yong Ji; Xin Wang Journal: Nat Commun Date: 2017-09-08 Impact factor: 14.919